Intensive lipid-lowering therapy in coronary artery disease: Implications of the REVERSAL and PROVE-IT trials

Expert Opinion on Investigational Drugs

Volumn 13, Issue 6, 2004, Pages 707-713

  Salam, Amar M ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Atorvastatin; Cholesterol; Coronary artery disease; Lipid lowering; Paper evaluation; Pravastatin; Statins; Trials

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ANTIBIOTIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLESTYRAMINE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FOLIC ACID; GATIFLOXACIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANGINA PECTORIS; ANGIOPLASTY; AORTA ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; HEART INFARCTION; HUMAN; INTRAVASCULAR ULTRASOUND; LIVER DYSFUNCTION; PRACTICE GUIDELINE; REVASCULARIZATION; REVIEW; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; HEPTANOIC ACIDS; HUMANS; PRAVASTATIN; PYRROLES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 3042723888     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.6.707     Document Type: Review

References (21)

1. NISSEN SE, TUZCU EM, SCHOENHAGEN P et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 291(9):1071-1080.
2. CANNON CP, BRAUNWALD E, McCABE CH et al.: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350(15):1495-1504.
3. EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2497.
4. DE BACKER G, AMBROSIONI E, BORCH-JOHNSEN K et al.: European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis. (2003) 171:145-155.
5. STAMLER J, WENTWORTH D, NEATON JD: Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA (1986) 256:2823-2828.
6. GRUNDY SM: Statin trials and goals of cholesterol-lowering therapy. Circulation (1998) 97:1436-1439.
7. SACKS FM, MOYE LA, DAVIS BR et al.: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation (1998) 97:1446-1452.
8. WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation (1998) 97:1440-1445.
9. PEDERSON TR, OLSSON AG, FAERGEMAN O et al.: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Study (45). Circulation (1998) 97:1453-1460.
10. THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. (1998) 339:1349-1357.
11. DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279:1615-1622.
12. HEART PROTECTION COLLABORATIVE STUDY GROUP: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7-22.
13. SALAM AM: Expanding indications of statins; implications of the Heart Protection Study. Expert Opin. Investig. Drugs (2003) 12:509-513.
14. POST CORONARY ARTERY BYPASS GRAFT TRIAL INVESTIGATORS: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation of obstructive changes in saphenous-vein coronary-artery bypass grafts. N. Engl. J. Med. (1997) 336:153-162.
15. PITT B, WATERS D, BROWN WV et al.: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N. Engl. J. Med. (1999) 341:70-76.
16. BROWN WV, AVERT I: Can aggressive lipid-lowering therapy provide additional clinical benefit? Subgroup analysis of the Atorvastatin VErsus Revascularization Treatments (AVERT) trial. Eur. Heart J. (2000) 21(Suppl.):157(Abstract).
17. SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA (2001) 285:1711-1718.
18. STENESTRAND U, WALLENTIN L: For the Swedish Register of Cardiac Intensive Care (RIKS-HIA): early statin treatment following acute myocardial infarction and 1-year survival. JAMA (2001) 285:430-436.
19. ARONOW HD, TOPOL EJ, ROE MT et al.: Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 357:1063-1068.
20. NEWBY LK, KRISTINSSON A, BHAPKAR MV et al.: Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA (2002) 287:3087-3095.
21. LIUZZO G, BIASUCCI LM, GALLIMORE JR et al.: Enhanced inflammatory response in patients with preinfarction unstable angina. J. Am. Coll. Cardiol. (1999) 34:1696-1703.